Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Gains from Sales and Divestitures: 2017-2023

Historic Gains from Sales and Divestitures for Ani Pharmaceuticals (ANIP) over the last 4 years, with Mar 2023 value amounting to $235,000.

  • Ani Pharmaceuticals' Gains from Sales and Divestitures rose 45.96% to $235,000 in Q1 2023 from the same period last year, while for Mar 2023 it was $235,000, marking a year-over-year increase of 45.96%. This contributed to the annual value of $245,000 for FY2022, which is 96.00% up from last year.
  • Latest data reveals that Ani Pharmaceuticals reported Gains from Sales and Divestitures of $235,000 as of Q1 2023, which was down 4.08% from $245,000 recorded in Q4 2022.
  • Ani Pharmaceuticals' Gains from Sales and Divestitures' 5-year high stood at $245,000 during Q4 2022, with a 5-year trough of $34,000 in Q1 2021.
  • Over the past 3 years, Ani Pharmaceuticals' median Gains from Sales and Divestitures value was $161,000 (recorded in 2022), while the average stood at $164,444.
  • Per our database at Business Quant, Ani Pharmaceuticals' Gains from Sales and Divestitures tumbled by 30.61% in 2021 and then skyrocketed by 373.53% in 2022.
  • Ani Pharmaceuticals' Gains from Sales and Divestitures (Quarterly) stood at $42,000 in 2019, then surged by 202.38% to $127,000 in 2020, then decreased by 1.57% to $125,000 in 2021, then spiked by 96.00% to $245,000 in 2022, then surged by 45.96% to $235,000 in 2023.
  • Its Gains from Sales and Divestitures stands at $235,000 for Q1 2023, versus $245,000 for Q4 2022 and $234,000 for Q3 2022.